Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Andrea K Miyahira; Kenneth J Pienta; John W Babich; Neil H Bander; Jeremie Calais; Peter Choyke; Michael S Hofman; Steven M Larson; Frank I Lin; Michael J Morris; Martin G Pomper; Shahneen Sandhu; Howard I Scher; Scott T Tagawa; Scott Williams; Howard R Soule

doi:10.1002/pros.24056

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Prostate. 2020 Nov;80(15):1273-1296. doi: 10.1002/pros.24056. Epub 2020 Aug 31.

Authors

Andrea K Miyahira¹, Kenneth J Pienta², John W Babich³, Neil H Bander⁴, Jeremie Calais⁵, Peter Choyke⁶, Michael S Hofman^{7

8}, Steven M Larson⁹, Frank I Lin⁶, Michael J Morris¹⁰, Martin G Pomper², Shahneen Sandhu^{7

11}, Howard I Scher^{10

12}, Scott T Tagawa¹³, Scott Williams^{7

14}, Howard R Soule¹

Affiliations

¹ Science Department, Prostate Cancer Foundation, Santa Monica, California.
² Department of Urology, The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Department of Radiology, Weill Cornell Medicine, New York, New York.
⁴ Laboratory of Urologic Oncology, Department of Urology and Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
⁵ Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
⁶ Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
⁷ Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.
⁸ Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.
⁹ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
¹⁰ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
¹¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.
¹² Department of Medicine, Weill Cornell Medical College, New York, New York.
¹³ Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.
¹⁴ Department of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.

Abstract

Introduction: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY.

Methods: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer.

Results: Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT.

Discussion: This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.

Keywords: PET imaging; clinical trials; medical oncology; nuclear medicine; prostate-specific membrane antigen (PSMA); radiation therapy; radiology; radionuclides; radiopharmaceuticals; urology.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Humans
Male
Molecular Targeted Therapy / methods
Precision Medicine
Prostatic Neoplasms / therapy*
Theranostic Nanomedicine

Abstract

Publication types

MeSH terms

Grants and funding